Professor of Surgery, Professor of Oncology, Johns Hopkins University School of Medicine; Melanoma Program Director
General Surgery
Dr. Suzanne L. Topalian, MD
|
|
Give Review
Dr. Suzanne L. Topalian practices General Surgery. She studied medicine at Tufts University School of Medicine. Tufts University School of Medicine is ranked 49/52 in Research/PrimaryCare. Dr. Suzanne L. Topalian is also a published doctor. She has 44 paper published. The most recent paper is: Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Publications
- PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
- Alterations of immune response of non-small cell lung cancer with Azacytidine.
- Structure-Based Design of Altered MHC Class II-Restricted Peptide Ligands with Heterogeneous Immunogenicity.
- PD-L1 expression in the Merkel cell carcinoma microenvironment: Association with inflammation, Merkel cell polyomavirus and overall survival.
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody.
- Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3.
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.
- Cancer Immunotherapy Comes of Age.
- Control of T(H)17/T(reg) Balance by Hypoxia-Inducible Factor 1.
- Opportunities and challenges in the development of experimental drug combinations for cancer.
- Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.
- Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
- Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
- Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.
- Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor.
- Cancer regression in patients after transfer of genetically engineered lymphocytes.
- Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma.
- Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
- Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
- Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
- Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
- Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.
- Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
- Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
- Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
- Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.
- Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.
- CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.
- Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR.
- Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
- Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
- Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
- A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
- Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
- Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
- Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
- Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression.
- Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
- Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme.
- A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.
- Tumor-specific CD8+ T lymphocytes derived from the peripheral blood of prostate cancer patients by in vitro stimulation with autologous tumor cell lines.
- Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.
Schools
Tufts University
Doctors Specialties
- General Surgery
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Thomas Jefferson University -
Children's Hospital of Philadelphia -
Tufts University School of Medicine
Hospital
-
Johns Hopkins Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. John L. Flowers, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric D. Strauch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alexander E. Pazoki, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roger W. Voigt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter S. Liao, MD |
|
|
Dr. Matthew J. Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca Craig-Schapiro, MD |
|
|
Dr. Motaharsadat Hosseini, MD |
|
|
Dr. Laurence H. Scipio, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Adil H. Haider, MB
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|